Ondansetron: Difference between revisions
Ostermayer (talk | contribs) (Prepared the page for translation) |
m (Danbot moved page Ondansteron to Ondansetron over redirect: Fixing misspelling: Ondansteron → Ondansetron) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 75: | Line 75: | ||
*Excretion: urine | *Excretion: urine | ||
*Mechanism of Action:selectively antagonizes serotonin 5-HT3 receptors | *Mechanism of Action:selectively antagonizes serotonin 5-HT3 receptors | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Ondansetron]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
Latest revision as of 03:03, 25 March 2026
General
- Type: antiemetics
- Dosage Forms: 4mg, 8mg
- Common Trade Names: Zofran
Adult Dosing
- Nausea/Vomiting: 4-8mg q4h, max 24mg a day
Pediatric Dosing
- Nausea/Vomiting: 0.1mg/kg IV q4h max dose at once:4-8mg, max 24mg
- Gastroenteritis - Vomiting
- 8 to 15 kg:
- 2mg orally disintegrating tablet dissolved orally as a single dose
- 15 to 30 kg:
- 4mg orally disintegrating tablet dissolved orally as a single dose
- Greater than 30 kg:
- 8mg orally disintegrating tablet dissolved orally as a single dose
- 8 to 15 kg:
Special Populations
- Pregnancy Rating: B
- Consider avoiding in 1st trimester; conflicting data regarding possible risk of teratogenicity
- Newer data argues that ondansetron is not the cause of birth defects[1]
- Lactation:safety unknown
- Renal Dosing:
- Adult: not defined
- Pediatric: not defined
- Hepatic Dosing: not defined
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- Congenital long QT syndrome
- Serotonin syndrome
Adverse Reactions
Serious
- bronchospasm
- steven-johnson syndrome
- QT prolongation
- torsades de pointes
- serotonin syndrome
- extrapyramidal symptoms
- blindness, transient
Common
- headache
- constipation
- fatigue
- hypoxia
- fever
- urinary retention
- agitation
Pharmacology
- Half-life: 4.6-5.7 hour
- Metabolism: liver
- Excretion: urine
- Mechanism of Action:selectively antagonizes serotonin 5-HT3 receptors
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Hyperemesis gravidarum | 4-8 mg q12hr | 3rd line antiemetic | IV | Adult |
See Also
References
- ↑ Fejzo MS, et al. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol. 2016 Jul;62:87-91.